NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BBIO

BridgeBio Pharma Inc

Jun 30 • 04:00PM ET

43.18

Dollar change -1.68
Percentage change -3.74	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: IWM VTI VB XBI VXF VBK IWO IBB SCHA XT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.53	Insider Own	15.39%	Shs Outstand	189.83M	Perf Week	2.38%
Market Cap	8.20B	Forward P/E	-	EPS next Y	-1.59	Insider Trans	-35.89%	Shs Float	160.76M	Perf Month	29.40%
Enterprise Value	10.03B	PEG	-	EPS next Q	-0.74	Inst Own	85.61%	Short Float	13.14%	Perf Quarter	22.98%
Income	-667.97M	P/S	64.35	EPS this Y	-4.12%	Inst Trans	4.91%	Short Ratio	6.87	Perf Half Y	51.35%
Sales	127.42M	P/B	-	EPS next Y	46.94%	ROA	-77.18%	Short Interest	21.12M	Perf YTD	57.36%
Book/sh	-8.68	P/C	15.16	EPS next 5Y	-	ROE	-	52W High	45.48 -5.06%	Perf Year	83.28%
Cash/sh	2.85	P/FCF	-	EPS past 3/5Y	9.60% -3.04%	ROIC	-95.16%	52W Low	21.72 98.80%	Perf 3Y	375.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.10% 40.48%	Gross Margin	92.24%	Volatility	4.21% 4.10%	Perf 5Y	32.37%
Dividend TTM	-	EV/Sales	78.68	EPS Y/Y TTM	-9.37%	Oper. Margin	-537.55%	ATR (14)	1.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.54	Sales Y/Y TTM	-41.71%	Profit Margin	-524.25%	RSI (14)	64.83	Recom	1.35
Dividend Gr. 3/5Y	- -	Current Ratio	4.57	EPS Q/Q	-346.73%	SMA20	6.27%	Beta	1.16	Target Price	61.06
Payout	-	Debt/Eq	-	Sales Q/Q	-44.76%	SMA50	16.13%	Rel Volume	1.78	Prev Close	44.86
Employees	730	LT Debt/Eq	-	Earnings	Apr 29 AMC	SMA200	37.18%	Avg Volume	3.08M	Price	43.18
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.13% 93.88%	Trades		Volume	5,465,277	Change	-3.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Wolfe Research	Outperform	$49
Mar-31-25	Initiated	Redburn Atlantic	Buy	$50
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	SVB Leerink	Outperform	$66 → $24
Dec-27-21	Reiterated	Mizuho	Buy	$86 → $25
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy	$75
May-21-21	Initiated	UBS	Buy	$80
Mar-22-21	Reiterated	Goldman	Buy	$83 → $91
Feb-22-21	Resumed	JP Morgan	Overweight	$78

Show Previous Ratings

Today 07:30AM	BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty (GlobeNewswire)
Jun-26-25 07:30AM	BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET (GlobeNewswire)
Jun-25-25 06:01AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks That Are Ticking Every Box (TipRanks)
Jun-24-25 04:25AM	Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results (Insider Monkey) +5.39%
Jun-11-25 07:54PM	BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright (Insider Monkey)
08:50AM	Loading…
Jun-05-25 08:50AM	BridgeBio price target raised to $42 from $37 at BMO Capital (TipRanks)
Jun-02-25 07:30AM	BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire)
May-23-25 03:21PM	Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
04:24AM	BridgeBio's Acoramidis: A Breakthrough in ATTR-CM Treatment (Insider Monkey)
May-20-25 09:40AM	Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year? (Zacks)
07:30AM	Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM (GlobeNewswire)
May-19-25 12:33PM	Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study (GlobeNewswire)
May-14-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:27AM	BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug (Clinical Trials Arena)
06:50AM	Loading…
06:50AM	Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday (Insider Monkey)
May-13-25 09:55AM	Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade (Zacks) -6.78%
07:30AM	First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study (GlobeNewswire)
May-12-25 07:30AM	BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC (GlobeNewswire)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
07:30AM	BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 (GlobeNewswire)
Apr-30-25 09:12PM	Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday (Insider Monkey) +5.33%
04:27PM	BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations (Investor's Business Daily)
12:31PM	Q1 2025 BridgeBio Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
10:04AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:07AM	BridgeBio sales of new heart drug outstrip expectations (BioPharma Dive)
03:17AM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Apr-29-25 09:43PM	BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	BridgeBio Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations (Investor's Business Daily)
04:01PM	BridgeBio Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
11:39AM	BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
10:29AM	UK MHRA authorises BridgeBios acoramidis for ATTR-CM (Pharmaceutical Technology)
Apr-28-25 07:18PM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
05:00AM	BEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM (GlobeNewswire)
Apr-23-25 10:01AM	Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-22-25 11:14AM	BridgeBio: Early Signs Point To Blockbuster Revenues (Seeking Alpha)
07:30AM	BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET (GlobeNewswire)
Apr-11-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-31-25 10:00AM	Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM (GlobeNewswire)
Mar-29-25 04:12PM	Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 07:00AM	Beyonttra (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved in Japan to Treat ATTR-CM (GlobeNewswire)
Mar-24-25 07:30AM	BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions (GlobeNewswire) +7.05%
Mar-21-25 05:37PM	Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (SeekingAlpha)
04:13PM	Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio (Investor's Business Daily)
04:00PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:04PM	Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug (Pharmaceutical Technology)
01:21PM	Alnylam Stock Jumps After the FDA Approves Its Heart Drug (The Wall Street Journal)
10:05AM	Alnylam Heart Drug Approval Sets Up Challenge With Pfizer (Bloomberg)
Mar-20-25 06:13PM	Alnylam nabs key additional indication for Amvuttra (SeekingAlpha)
Mar-17-25 04:01PM	BridgeBio Announces CFO Succession (GlobeNewswire)
Mar-03-25 07:16AM	BridgeBio Oncology and Helix enter definitive merger agreement (Pharmaceutical Technology) -5.42%
Feb-28-25 06:50AM	BridgeBio oncology spinout to go public in blank-check merger (BioPharma Dive)
Feb-26-25 11:56AM	BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
02:49AM	BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt (GlobeNewswire)
Feb-24-25 04:09PM	BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt (GlobeNewswire) -5.24%
Feb-23-25 03:07PM	Why BridgeBio Pharma, Inc. (BBIO) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-22-25 09:20AM	BridgeBio price target raised to $52 from $49 at Scotiabank (TipRanks)
Feb-21-25 05:13PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Feb-20-25 08:57AM	BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
08:55AM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:49AM	BridgeBio Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update (GlobeNewswire)
05:53AM	BridgeBios heart drug launch gets off to a fast start (BioPharma Dive)
Feb-13-25 04:01PM	BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 (GlobeNewswire) +10.58%
10:48AM	BridgeBio price target raised to $49 from $48 at Scotiabank (TipRanks)
Feb-12-25 06:40AM	EC grants marketing authorisation to BridgeBios ATTR-CM treatment (Pharmaceutical Technology)
Feb-11-25 09:21AM	BEYONTTRA (acoramidis), the First Near Complete TTR Stabilizer ( 90%), Approved by the European Commission to Treat ATTR-CM (GlobeNewswire)
06:38AM	Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK (BioPharma Dive)
Feb-08-25 08:46AM	Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-07-25 07:16PM	DHT, Evolve Technologies, and More Stocks See Action From Activist Investors (Barrons.com)
07:16PM	DHT, Evolv Technologies, and More Stocks See Action From Activist Investors (Barrons.com)
Feb-04-25 08:58AM	Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday (Insider Monkey) +6.28%
Jan-29-25 04:00PM	Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025? (Insider Monkey)
Jan-26-25 03:07AM	Why BridgeBio Pharma (BBIO) Is Skyrocketing Now (Insider Monkey)
Jan-23-25 06:42AM	Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now? (Insider Monkey)
02:00AM	BridgeBios Neil Kumar on an underdog drug launch and wooing deal-hungry investors (BioPharma Dive)
Jan-15-25 08:58AM	Is BridgeBio Pharma, Inc. (BBIO) Among Tuesdays Top Gainers? (Insider Monkey)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily) +5.56%
10:00AM	Why BridgeBio Pharma (BBIO) Led the Monday Upsurge? (Insider Monkey)
04:59AM	Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength? (Zacks)
Jan-13-25 06:54PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) +15.99%
04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
11:00AM	BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones (GlobeNewswire)
Jan-08-25 07:30AM	BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-24-24 08:40AM	BridgeBio price target raised to $50 from $45 at Evercore ISI (TipRanks)
Dec-13-24 07:18AM	Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Dec-03-24 08:00AM	Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology (GlobeNewswire)
Nov-26-24 09:10AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
06:50AM	BridgeBio price target raised to $45 from $42 at BofA (TipRanks)
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily) +16.10%
09:40AM	BridgeBio Soars After Drug Gets Nod in Rare Heart Condition (Bloomberg)
09:03AM	FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market (Benzinga)
04:38AM	FDA approves BridgeBios Attruby for ATTR-CM treatment (Pharmaceutical Technology)
Nov-22-24 07:11PM	Attruby (acoramidis), a Near Complete TTR Stabilizer ( 90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients (GlobeNewswire)
02:16PM	BridgeBio heart drug approved by FDA, setting up battle with Pfizer (BioPharma Dive)
Nov-21-24 05:43PM	Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 02:44PM	BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market (Benzinga)
Nov-18-24 11:15AM	Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months (GlobeNewswire) -5.78%

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCCORMICK FRANK	Director	Jun 24 '25	Sale	44.23	100,000	4,422,800	879,979	Jun 26 05:08 PM
DENIS VON KAEPPLER IRA ROLLOVE	client's wife is a BoD	Jun 26 '25	Proposed Sale	44.03	1,891	83,261		Jun 26 04:19 PM
HANNAH VALANTINE & DENIS VON K	spouse of bod / bod is joint o	Jun 26 '25	Proposed Sale	44.01	1,542	67,863		Jun 26 04:16 PM
HANNAH A VALANTINE & DENIS VON	Officer	Jun 26 '25	Proposed Sale	44.11	876	38,640		Jun 26 04:14 PM
ERICKA VON KAEPPLER & DENIS VO	account owners are spouse and	Jun 26 '25	Proposed Sale	44.13	398	17,562		Jun 26 04:13 PM
MCCORMICK FRANK	Officer	Jun 24 '25	Proposed Sale	44.23	100,000	4,422,803		Jun 24 05:59 PM
Valantine Hannah	Director	Jun 10 '25	Option Exercise	16.75	4,292	71,891	6,056	Jun 11 05:00 PM
Valantine Hannah	Director	Jun 10 '25	Sale	40.00	4,292	171,680	1,764	Jun 11 05:00 PM
HANNAH A VALANTINE	Director	Jun 10 '25	Proposed Sale	40.00	4,292	171,680		Jun 10 04:01 PM
Kumar Neil	Chief Executive Officer	May 20 '25	Sale	33.40	75,000	2,504,978	4,798,447	May 20 06:06 PM
Kumar Neil	Chief Executive Officer	May 19 '25	Sale	33.33	26,156	871,764	217,404	May 20 06:06 PM
NEIL KUMAR	Director	May 19 '25	Proposed Sale	33.84	26,156	885,119		May 19 04:25 PM
KKR Genetic Disorder L.P.	10% Owner	May 12 '25	Sale	34.20	6,000,000	205,200,000	13,260,971	May 14 05:24 PM
KKR Genetic Disorder L.P.	Affiliate	May 12 '25	Proposed Sale	35.68	6,000,000	214,080,000		May 12 09:46 PM
Apuli Maricel	Chief Accounting Officer	May 02 '25	Sale	38.51	1,026	39,509	147,639	May 06 04:45 PM
Lo Andrew	Director	May 02 '25	Sale	38.50	100,000	3,849,900	105,583	May 06 04:42 PM
Lo Andrew	Director	May 02 '25	Proposed Sale	35.23	100,000	3,523,000		May 02 04:36 PM
Kumar Neil	Chief Executive Officer	Apr 22 '25	Sale	34.11	75,000	2,558,025	4,873,447	Apr 24 04:28 PM
Ellis Andrea	Director	Apr 14 '25	Option Exercise	8.45	10,000	84,500	22,000	Apr 16 05:39 PM
Ellis Andrea	Director	Apr 14 '25	Sale	35.00	10,000	350,000	12,000	Apr 16 05:39 PM
ANDREA ELLIS	Director	Apr 14 '25	Proposed Sale	35.00	10,000	350,000		Apr 14 04:21 PM
Ellis Andrea	Director	Apr 01 '25	Option Exercise	8.45	30,000	253,500	42,000	Apr 03 05:11 PM
Ellis Andrea	Director	Apr 01 '25	Sale	34.05	30,000	1,021,500	12,000	Apr 03 05:11 PM
ANDREA ELLIS	Director	Apr 01 '25	Proposed Sale	34.05	30,000	1,021,500		Apr 02 04:48 PM
Kumar Neil	Chief Executive Officer	Mar 25 '25	Sale	36.87	75,000	2,764,943	4,948,447	Mar 27 04:54 PM
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM
BRIAN STEPHENSON	Officer	Feb 25 '25	Proposed Sale	36.25	34,000	1,232,500		Feb 25 04:34 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Feb 19 '25	Sale	36.16	4,148	149,973	102,464	Feb 19 08:50 PM
Kumar Neil	Chief Executive Officer	Feb 19 '25	Sale	36.14	31,543	1,140,024	211,718	Feb 19 08:48 PM
NEIL KUMAR	Director	Feb 19 '25	Proposed Sale	35.49	31,543	1,119,461		Feb 19 04:31 PM
BRIAN STEPHENSON	Officer	Feb 19 '25	Proposed Sale	35.49	4,148	147,213		Feb 19 04:31 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Proposed Sale	34.90	3,065,616	106,989,998		Jan 31 07:18 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Sale	34.90	3,065,616	106,989,998	22,055,375	Jan 31 07:18 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Option Exercise	17.00	68,000	1,156,000	161,758	Jan 30 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Sale	36.29	68,000	2,467,761	93,758	Jan 30 06:31 PM
Kumar Neil	Chief Executive Officer	Jan 28 '25	Sale	36.29	326,932	11,863,381	5,371,515	Jan 30 06:29 PM
Kumar Neil	Chief Executive Officer	Jan 29 '25	Sale	36.35	273,068	9,925,269	5,098,447	Jan 30 06:29 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 28 '25	Proposed Sale	36.67	600,000	22,002,000		Jan 28 04:18 PM
BRIAN STEPHENSON	Officer	Jan 28 '25	Proposed Sale	36.67	68,000	2,493,560		Jan 28 04:18 PM
Satvat Ali J.	Director	Dec 30 '24	Option Exercise	16.22	159,404	2,585,134	159,404	Dec 31 05:52 PM
Kumar Neil	Chief Executive Officer	Nov 19 '24	Sale	22.41	27,389	613,826	4,897,443	Nov 20 08:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Nov 19 '24	Sale	22.41	4,156	93,137	93,758	Nov 20 07:57 PM
BRIAN STEPHENSON	Officer	Nov 19 '24	Proposed Sale	22.35	4,156	92,887		Nov 19 04:28 PM
NEIL KUMAR	Director	Nov 19 '24	Proposed Sale	22.35	27,389	612,144		Nov 19 04:24 PM
KKR Genetic Disorder L.P.	10% Owner	Sep 13 '24	Sale	25.75	5,800,000	149,350,000	25,260,971	Sep 17 06:44 PM
KKR Genetic Disorder L.P.	Affiliate	Sep 13 '24	Proposed Sale	26.95	5,800,000	156,310,000		Sep 13 05:04 PM
Kumar Neil	Chief Executive Officer	Aug 19 '24	Sale	24.69	27,389	676,256	4,897,443	Aug 20 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Aug 19 '24	Sale	24.69	4,155	102,590	85,192	Aug 20 06:27 PM
BRIAN STEPHENSON	Officer	Aug 19 '24	Proposed Sale	24.40	4,155	101,382		Aug 19 04:29 PM
NEIL KUMAR	Director	Aug 19 '24	Proposed Sale	24.40	27,389	668,292		Aug 19 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BBIO

BridgeBio Pharma Inc

Upgrade your FINVIZ experience